We are live on
!
Find out more
Atossa Therapeutics
ATOS
ATOS
15 hedge funds and large institutions have $513K invested in Atossa Therapeutics in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 14 → 15 (+1)
0.01% more ownership
Funds ownership: 0.19% → 0.19% (+0.01%)
21% less capital invested
Capital invested by funds: $649K → $513K (-$136K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
2
Closed
4
Calls
$24K
Puts
–
Net Calls
+$24K
Net Calls Change
-$19K
Top Buyers
| 1 |
Northern Trust
Chicago,
Illinois
|
+$26.4K |
| 2 |
JP Morgan Chase
New York
|
+$24K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$3.45K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.98K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$823 |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$21.8K |
| 2 |
Barclays
London,
United Kingdom
|
-$11.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6K |
| 4 |
Morgan Stanley
New York
|
-$3.8K |